A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234) - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)
Can we lower the chance of gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into the abdominal cavity in addition to chemotherapy given through a vein in the arm? Will administering paclitaxel chemotherapy directly into the abdominal cavity, in addition to chemotherapy given through a vein in the arm help patients live longer?
Clinical Scorecard: A Trial of Intraperitoneal Paclitaxel Plus Chemotherapy Given Through a Vein in the Arm for Gastric Cancer (NCT07001748)
At a Glance
Category
Detail
Condition
Gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis
Key Mechanisms
The study asks whether paclitaxel administered directly into the abdominal cavity, in addition to chemotherapy given through a vein in the arm, can reduce the chance of gastric cancer growing or spreading and help patients live longer.
Target Population
The listed diseases are gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis; specific eligibility criteria are not provided.
Care Setting
The study compares paclitaxel administered directly into the abdominal cavity in addition to chemotherapy given through a vein in the arm with the usual approach for gastric cancer.
Key Highlights
The study asks whether adding paclitaxel administered directly into the abdominal cavity to chemotherapy given through a vein in the arm can reduce the chance of gastric cancer growing or spreading.
The study also asks whether this approach can help patients live longer.
The source does not report trial results.
Guideline-Based Recommendations
Diagnosis
Management
The study evaluates intraperitoneal paclitaxel added to chemotherapy given intravenously; it does not provide a treatment recommendation.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The listed diseases are gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis. Specific eligibility criteria are not provided.
The study asks about adding paclitaxel administered into the abdominal cavity to chemotherapy given through a vein in the arm; the source describes the comparison as the usual approach for gastric cancer.
Clinical Best Practices
For eligibility information, the source directs patients to contact the study team at 215-214-1515 or use the trial inquiry form.
The source directs readers to ClinicalTrials.gov for the full clinical trial description.